InvenSense Inc (NASDAQ:INVN): ThinkEquity believes InvenSense, near-term fundamentals, are intact and they should meet or slightly beat their June quarter. The company remains confident in InvenSense’s long-term prospects, and reiterates its Buy rating and $20 price target.
VeriSign Inc. (NASDAQ:VRSN): Last night, the U.S Department of Commerce announced, they will be renewing their contract with the Internet Corporation for Assigned Names and Numbers (ICANN), as noted by JP Morgan. This will fulfill the Internet Assigned Numbers Authority, or IANA function. The company believes that this news removes any uncertainty that investors may have had concerning VeriSign.com’s November 2012, renewal contract. JPMorgan has a Neutral rating on shares of VeriSign, and points out that the renewal of ICANN’s contract does not directly impact the .com renewal.
FormFactor Inc. (NASDAQ:FORM): After Micron (NASDAQ:MU) agreed to purchase Elpida, Stifel Nicolaus believes that FormFactor is poised to benefit over the long-term from the deal. The firm maintains a $12 target and Buy rating on FormFactor.
Nxstage Medical, Inc. (NASDAQ:NXTM): Last night, according to Leerink, the Centers for Medicare & Medicaid Services released their proposal for 2013 outpatient reimbursement and maintained the status quo for hemodialysis. The firm believes the status quo is likely priced into NxStage Medical shares, but says the lack of any change could be viewed as disappointing since it removes a potential source of near-term upside. Leerink keeps an Outperform rating on shares of NxStage Medical.
Photronics Inc. (NASDAQ:PLAB): Stifel Nicolaus expects Phototronics to obtain a new revenue stream from Elpida, after Micron (NASDAQ:MU)agreed to buy the company. This is comes as a result of Micron’s decision to transition the European company to a different DRAM node. The firm maintains an $11 target and Buy rating on Phototronics.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.